Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 9;14(19):2905.
doi: 10.3390/ani14192905.

Allogenic Adipose-Derived Mesenchymal Stem Cell Infusion for the Management of Acute-Onset Pancreatitis in Dogs: A Pilot Study

Harry Cridge  1 , Valerie Johnson  1
Affiliations

Allogenic Adipose-Derived Mesenchymal Stem Cell Infusion for the Management of Acute-Onset Pancreatitis in Dogs: A Pilot Study

Harry Cridge et al. Animals (Basel). .

Abstract

Mesenchymal stem cells (MSCs) have significant anti-inflammatory properties and are beneficial in rodent models of pancreatitis. The safety and efficacy of MSCs is unknown in dogs with acute pancreatitis (AP). Dogs with AP who were treated with MSCs (n = 4) were identified prospectively for this pilot study from an academic hospital. Serum Spec cPL and C-reactive protein (CRP) concentrations were measured on the day of MSC administration and 2 days later. The clinical severity, via the Modified Clinical Activity Index (MCAI), was also calculated. Two dogs received MSCs shortly after AP diagnosis, while the remaining dogs received MSCs due to clinically refractory disease. Changes in Spec cPL, CRP, and MCAI in the MSC-treated dogs were compared to a control population (n = 7) receiving the standard-of-care treatment for AP. No significant differences were noted between the populations for changes in Spec cPL (p = 0.79), CRP (p = 0.67), or MCAI (p = 0.91). However, subjective clinical improvements were noted within 24 h of MSC infusion in the two dogs with previously refractory disease. MSC infusions appear safe in the management of AP in dogs and may be considered in refractory disease. However, given the nature of this pilot study and its limitations, larger randomized controlled clinical trials are needed to truly evaluate the efficacy of MSC infusions in dogs with AP.

Keywords: MSC; Spec cPL; cPLI; pancreatitis; refractory disease.

PubMed Disclaimer

Conflict of interest statement

Dr. Cridge is a paid speaker and content developer for CEVA Animal Health LLC, who market and distribute fuzapladib sodium in the United States. Dr. Cridge is also the recipient of research funding from CEVA Animal Health LLC. No funding was received for this project. Dr. Johnson has no conflicts of interest.

References

    1. Hess R.S., Kass P.H., Shofer F.S., Van Winkle T.J., Washabau R.J. Evaluation of risk factors for fatal acute pancreatitis in dogs. J. Am. Vet. Med. Assoc. 1999;214:46–51. doi: 10.2460/javma.1999.214.01.46. - DOI - PubMed
    1. Gori E., Pierini A., Lippi I., Ceccherini G., Perondi F., Marchetti V. Evaluation of C-reactive protein/albumin ratio and its relationship with survival in dogs with acute pancreatitis. N. Z. Vet. J. 2020;68:345–348. doi: 10.1080/00480169.2020.1780995. - DOI - PubMed
    1. Kuzi S., Mazaki-Tovi M., Suchodolski J.S., Rimer D., Lidbury J.A., Steiner J.M., Buono A., Nivy R., Segev G., Aroch I. Protease inhibitors, inflammatory markers, and their association with outcome in dogs with naturally occurring acute pancreatitis. J. Vet. Intern. Med. 2020;34:1801–1812. doi: 10.1111/jvim.15895. - DOI - PMC - PubMed
    1. Okanishi H., Nagata T., Nakane S., Watari T. Comparison of initial treatment with and without corticosteroids for suspected acute pancreatitis in dogs. J. Small Anim. Pract. 2019;60:298–304. doi: 10.1111/jsap.12994. - DOI - PubMed
    1. Steiner J.M., Lainesse C., Noshiro Y., Domen Y., Sedlacek H., Bienhoff S.E., Doucette K.P., Bledsoe D.L., Shikama H. Fuzapladib in a randomized controlled multicenter masked study in dogs with presumptive acute onset pancreatitis. J. Vet. Intern. Med. 2023;37:2084–2092. doi: 10.1111/jvim.16897. - DOI - PMC - PubMed

LinkOut - more resources